iBio, Inc. (NYSEMKT:IBIO) has been tagged as a play on the Ebola virus in recent weeks. The company “develops and offers pharmaceutical product applications using its iBioLaunch platform. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines,” according to a profile from its corporate website. iBio, Inc. (NYSEMKT:IBIO) in last trading activity moved up 66.67% to close at $2.45. Company weekly performance is 184.88% while its quarterly performance stands at 444.44%. iBio, Inc. (NYSEMKT:IBIO) is 56.05% away from its 52 week high.
On October 11, Technology giant Symantec Corporation(NASDAQ:SYMC) will be divided into two separate companies as one will concentrate on the computer security segment while the other will deal with information management. On last trading day Symantec Corporation (NASDAQ:SYMC) moved up 1.41% to close at $22.25. Its volatility for the week is 3.88% while volatility for the month is 2.06%. SYMC’s sales growth for past 5 years was 1.70% and its EPS growth for past 5 years was 16.60%. Symantec Corporation (NASDAQ:SYMC) monthly performance is -9.29%.
Pfizer Inc. (NYSE:PFE) announced, that the New Drug Application (NDA) for its drug palbociclib has received “Priority Review Designation” from the US Food and Drug Administration (FDA). The designation will accelerate the timing of review by the FDA from 10 months to approximately six months. On last trading day Pfizer Inc. (NYSE:PFE) fell -2.27% to close at $28.47. Its volatility for the week is 2.12% while volatility for the month is 1.59%. PFE’s sales growth for past 5 years was 1.30% and its EPS growth for past 5 years was 6.80%. Pfizer Inc. (NYSE:PFE) monthly performance is -3.26%.
CTI BioPharma Corp (NASDAQ:CTIC) EVP Matthew Plunkett sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $2.39, for a total transaction of $28,680.00. Following the completion of the sale, the executive vice president now directly owns 429,968 shares in the company, valued at approximately $1,027,624. CTI BioPharma Corp. (NASDAQ:CTIC) has 4.10% insider ownership while its institutional ownership stands at 28.00%. In last trading activity company’s stock closed at $2.24.
Buckingham Research upgraded shares of General Dynamics Corporation (NYSE:GD) from a neutral rating to a buy rating in a report issued on Monday, TheFlyOnTheWall.com reports. They currently have $144.00 target price on the stock, up from their previous target price of $130.00. On Monday shares of General Dynamics Corporation (NYSE:GD) closed at $118.27. Company’s sales growth for last 5 years was 1.30% and EPS growth for next 5 years is recorded as 8.29%.